# A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

> **NCT01334918** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 124 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** regadenoson
- **RADIATION:** technetium Tc99m sestamibi /technetium Tc99m tetrafosmin
- **RADIATION:** Contrast
- **PROCEDURE:** Single Photon Emission Computed Tomography
- **PROCEDURE:** Multidetector Computed Tomography

## Key facts

- **NCT ID:** NCT01334918
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-26
- **Primary completion:** 2012-07-02
- **Final completion:** 2012-07-02
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01334918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01334918, "A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01334918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*